Advances In Therapy Added To Springer Journals Portfolio
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Public Health; Biology / Biochemistry
Article Date: 01 Nov 2007 - 7:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
3 (2 votes) |
As part of its continued commitment to providing high-quality information to professionals in the pharmaceutical industry, Springer has acquired the prestigious journal Advances in Therapy, to be published from 2008. With this move, Springer further enhances its services for clients in the pharmaceutical, healthcare and biotechnology industries.
Advances in Therapy, to be published by Springer Healthcare Communications (SHC), will continue to publish original research from the academic and research community across the globe as well as drug reviews and commissioned articles. Now in its 24th year of publication, the journal is Medline Indexed and has a strong Impact Factor, listed in both the ISI subject categories 'Pharmacology and Pharmacy' and 'Medicine, Research and Experimental'. The first issue of Advances in Therapy published by SHC will be Volume 25, No. 1, 2008.
The key feature of Advances in Therapy is the rapid publication of original research. Continuing this practice, SHC will increase its already rapid publication times to ensure online availability through SpringerLink within six weeks of submission. From 2008, Advances in Therapy will double its publication frequency from bimonthly to monthly.
Stephen Entwistle, Vice President of SHC, said, "Advances in Therapy works closely with pharmaceutical researchers to deliver clinically important results to the academic and industrial community. I am very proud that the journal is now part of the Springer family and I am confident that the journal's inclusion on SpringerLink will speed dissemination of important research worldwide."
###
Springer (http://www.springer.com/) is the second-largest publisher of journals in the science, technology, and medicine (STM) sector and the largest publisher of STM books. Springer Healthcare Communications offers the full range of communication and publishing strategies to develop high-impact medical education campaigns. The service portfolio includes strategic communications, publication planning, key opinion leader support, congress materials and events, as well as internet-based tools and promotional material.
Springer and SHC are part of Springer Science+Business Media, one of the world's leading suppliers of scientific and specialist literature. The group publishes over 1,700 journals and more than 5,500 new books a year, as well as the largest STM eBook Collection worldwide. Springer has operations in over 20 countries in Europe, the USA, and Asia, and some 5,000 employees.
Advances in Therapy ISSN: 0741-238X
Source: Renate Bayaz
Springer
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87394.php>
APA
http://www.medicalnewstoday.com/releases/87394.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




